RxDoctor Payments Data

Alexia Rowley

Family · Austin, TXNPI 1588085930

Payments from drug & device makers

$4,100in general payments, 2019–2025

Across 121 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$973
  • Regeneron Healthcare Solutions, Inc.$603
  • GSK$498
  • Boehringer Ingelheim$494
  • AstraZeneca$194
  • Insmed, Inc.$154
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$63015%
  • Food & beverage$3,38082%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,100 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$35,760
Medicare patients
170
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter174$190,495
Dupixent PenDupilumab15$55,724
Breo ElliptaFluticasone/Vilanterol97$54,935
Breztri AerosphereBudesonide/Glycopyr/Formoterol58$44,477
Spiriva RespimatTiotropium Bromide40$26,529
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$22,663
EliquisApixaban14$18,045
SymbicortBudesonide/Formoterol Fumarate47$16,572
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$15,050
DuleraMometasone/Formoterol24$10,647
BreynaBudesonide/Formoterol Fumarate36$9,190
Arnuity ElliptaFluticasone Furoate27$8,040
Advair HfaFluticasone Propion/Salmeterol12$7,375
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$5,770
Albuterol Sulfate HfaAlbuterol Sulfate161$5,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$498$268,520318 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$194$66,818116 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$494$49,19277 claims
MerckDulera$57$10,64724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →